Fatal post-viral neurodegenerative disorder

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:391343G04.8
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Fatal post-viral neurodegenerative disorder is an extremely rare condition in which the brain and nervous system progressively break down after a viral infection. In this disease, a person who has had a viral illness — often one that seemed routine at first — develops severe and worsening neurological problems afterward. The virus appears to trigger a process that damages nerve cells in the brain and spinal cord, leading to a rapid decline in brain function. Symptoms typically include progressive loss of mental abilities, movement problems, seizures, difficulty speaking and swallowing, and eventually loss of consciousness. The condition worsens over time and is unfortunately fatal, as the brain damage becomes too severe for the body to sustain normal life functions. There is currently no cure or proven disease-modifying treatment for this condition. Care is focused on managing symptoms, providing comfort, and supporting the patient and family. Because this disorder is so rare, research is limited, and much remains unknown about exactly why some people develop this devastating response to a viral infection while most others recover normally. Early recognition and referral to specialized neurological care is important, though outcomes remain very poor even with the best available supportive treatment.

Key symptoms:

Rapid decline in thinking and memorySeizuresDifficulty walking or movingMuscle stiffness or spasmsTrouble speakingDifficulty swallowingVision problemsPersonality or behavior changesLoss of consciousness or comaInvoluntary muscle jerks (myoclonus)Extreme fatigue and weaknessLoss of coordinationBreathing difficulties in advanced stages

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Fatal post-viral neurodegenerative disorder.

View clinical trials →

No actively recruiting trials found for Fatal post-viral neurodegenerative disorder at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Fatal post-viral neurodegenerative disorder community →

Specialists

1 foundView all specialists →
ZM
Zara M. Patel, MD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Fatal post-viral neurodegenerative disorder.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Fatal post-viral neurodegenerative disorderForum →

No community posts yet. Be the first to share your experience with Fatal post-viral neurodegenerative disorder.

Start the conversation →

Latest news about Fatal post-viral neurodegenerative disorder

No recent news articles for Fatal post-viral neurodegenerative disorder.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What virus triggered this condition, and does that affect the expected course?,Are there any experimental treatments or clinical trials we should consider?,What symptoms should we watch for that would require emergency care?,When should we involve palliative care or hospice services?,Could other family members be at risk if they get the same virus?,What support services are available for our family during this time?,How can we best manage pain and keep our loved one comfortable?

Common questions about Fatal post-viral neurodegenerative disorder

What is Fatal post-viral neurodegenerative disorder?

Fatal post-viral neurodegenerative disorder is an extremely rare condition in which the brain and nervous system progressively break down after a viral infection. In this disease, a person who has had a viral illness — often one that seemed routine at first — develops severe and worsening neurological problems afterward. The virus appears to trigger a process that damages nerve cells in the brain and spinal cord, leading to a rapid decline in brain function. Symptoms typically include progressive loss of mental abilities, movement problems, seizures, difficulty speaking and swallowing, and ev

How is Fatal post-viral neurodegenerative disorder inherited?

Fatal post-viral neurodegenerative disorder follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Which specialists treat Fatal post-viral neurodegenerative disorder?

1 specialists and care centers treating Fatal post-viral neurodegenerative disorder are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.